Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.

Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Geschwind JF.

Curr Pharm Biotechnol. 2010 Aug;11(5):510-7. Review.

PMID:
20420565
2.

Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting.

Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF.

Anticancer Res. 2013 Jan;33(1):13-20. Review.

PMID:
23267123
3.

Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug.

Cardaci S, Desideri E, Ciriolo MR.

J Bioenerg Biomembr. 2012 Feb;44(1):17-29. doi: 10.1007/s10863-012-9422-7. Review.

PMID:
22328057
4.

3-Bromopyruvate: targets and outcomes.

Shoshan MC.

J Bioenerg Biomembr. 2012 Feb;44(1):7-15. doi: 10.1007/s10863-012-9419-2. Review.

PMID:
22298255
5.

Mitochondria: 3-bromopyruvate vs. mitochondria? A small molecule that attacks tumors by targeting their bioenergetic diversity.

Galina A.

Int J Biochem Cell Biol. 2014 Sep;54:266-71. doi: 10.1016/j.biocel.2014.05.013. Epub 2014 May 16.

PMID:
24842108
6.

Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent.

Dell'Antone P.

Med Chem. 2009 Nov;5(6):491-6.

PMID:
19534685
7.

A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside.

Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL.

J Bioenerg Biomembr. 2012 Feb;44(1):163-70. doi: 10.1007/s10863-012-9417-4. Epub 2012 Feb 11.

PMID:
22328020
8.

Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.

Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT, Galina A.

Biochem J. 2009 Feb 1;417(3):717-26. doi: 10.1042/BJ20080805.

PMID:
18945211
10.

Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.

Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF.

J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):95-101.

PMID:
17296709
11.

The cancer cell's "power plants" as promising therapeutic targets: an overview.

Pedersen PL.

J Bioenerg Biomembr. 2007 Feb;39(1):1-12. Review.

PMID:
17404823
14.

D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate.

El Sayed SM, Abou El-Magd RM, Shishido Y, Chung SP, Sakai T, Watanabe H, Kagami S, Fukui K.

Cancer Gene Ther. 2012 Jan;19(1):1-18. doi: 10.1038/cgt.2011.59. Epub 2011 Sep 16.

PMID:
21921941
15.

Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.

Zhang X, Varin E, Briand M, Allouche S, Heutte N, Schwartz L, Poulain L, Icard P.

Anticancer Res. 2009 Apr;29(4):1443-8.

16.

Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect).

El Sayed SM, Mahmoud AA, El Sawy SA, Abdelaal EA, Fouad AM, Yousif RS, Hashim MS, Hemdan SB, Kadry ZM, Abdelmoaty MA, Gabr AG, Omran FM, Nabo MM, Ahmed NS.

Med Hypotheses. 2013 Nov;81(5):866-70. doi: 10.1016/j.mehy.2013.08.024. Epub 2013 Sep 3.

PMID:
24071366
17.

Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.

Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D.

Clin Cancer Res. 2008 Mar 15;14(6):1831-9. doi: 10.1158/1078-0432.CCR-07-1607.

18.

3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

El Sayed SM, El-Magd RM, Shishido Y, Chung SP, Diem TH, Sakai T, Watanabe H, Kagami S, Fukui K.

J Bioenerg Biomembr. 2012 Feb;44(1):61-79. doi: 10.1007/s10863-012-9409-4. Epub 2012 Feb 9.

PMID:
22318356
19.

3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs.

Ihrlund LS, Hernlund E, Khan O, Shoshan MC.

Mol Oncol. 2008 Jun;2(1):94-101. doi: 10.1016/j.molonc.2008.01.003. Epub 2008 Jan 13.

20.

Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.

Pathania D, Millard M, Neamati N.

Adv Drug Deliv Rev. 2009 Nov 30;61(14):1250-75. doi: 10.1016/j.addr.2009.05.010. Epub 2009 Aug 27. Review.

PMID:
19716393

Supplemental Content

Support Center